Skip to content

TECPR2 Observational Study

A Natural History Study in Children With a TECPR2 Mutation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04485221
Enrollment
5
Registered
2020-07-24
Start date
2021-01-20
Completion date
2023-08-17
Last updated
2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

TECPR2

Brief summary

The purpose of this study is to learn more about the disease progression in patients with a TECPR2 mutation.

Detailed description

A mutation in the tectonin beta-propeller repeat containing 2 (TECPR2) gene can disrupt the cellular process of autophagy resulting in neuronal cell death. This disruption leads to a form of spastic paraplegia with the additional disruption to involuntary body processes, such as respiration and thermoregulation. This study will provide valuable information about the natural progression of children with a TECPR2 mutation.

Interventions

None listed

Sponsors

University of Florida
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Months to 12 Years
Healthy volunteers
No

Inclusion criteria

* Written informed consent (and assent where appropriate) before any study procedures take place; * Male or female; * 18 months to 12 years old, at enrollment; and * Have a diagnosis of TECPR2-Related disorder, as defined by biochemical criteria AND/OR genetic mutation analysis, AND demonstrate clinical findings such as autophagy, developmental delay, hypotonia, or other positive findings.

Exclusion criteria

* Subject is unable to comply with study requirements; or * Have any other concurrent condition that, in the opinion of the investigator, would make the subject unsuitable for the study.

Design outcomes

Primary

MeasureTime frameDescription
Disease progressionBaseline up to 24 monthsThis will be monitored through medical history, physical exams, and a neurological exam.

Secondary

MeasureTime frameDescription
Functional assessment: Gross Motor Function Classification SystemBaseline up to 24 monthsThis measures the functional level of the patient based on their age.
Functional assessment: Timed TestsBaseline up to 24 monthsTimed tests for ambulant children will include time to run 10 meters, time to climb four stairs, and time to rise from the floor from supine.
Functional assessment: Muscular Strength TestingBaseline up to 24 monthsMuscle strength will be assessed for grip, pinch, quadriceps, hamstrings, biceps, and triceps.
Functional assessment: Gross Motor Function MeasureBaseline up to 24 monthsThis evaluative measure of motor function is designed for quantifying change in the gross motor abilities of children.
Patient Reported Outcomes: Pediatric Quality of Life InventoryBaseline up to 24 monthsA questionnaire used for measuring health-related quality of life in healthy children and adolescents and those with acute and chronic illnesses.
Patient Reported Outcomes: Pediatric Evaluation of Disability Inventory Computer Adaptive TestBaseline up to 24 monthsThis questionnaire measures the extent to which the caregiver or child takes responsibility for managing complex, multi-step life tasks.
Functional assessment: Ankle Dorsiflexion Range of MotionBaseline up to 24 monthsThis measurement is used to evaluate the degree of ankle contracture in a participant.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026